Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 185

1.

Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis.

Ebright RY, Lee S, Wittner BS, Niederhoffer KL, Nicholson BT, Bardia A, Truesdell S, Wiley DF, Wesley B, Li S, Mai A, Aceto N, Vincent-Jordan N, Szabolcs A, Chirn B, Kreuzer J, Comaills V, Kalinich M, Haas W, Ting DT, Toner M, Vasudevan S, Haber DA, Maheswaran S, Micalizzi DS.

Science. 2020 Feb 6. pii: eaay0939. doi: 10.1126/science.aay0939. [Epub ahead of print]

PMID:
32029688
2.

Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.

Brandao LR, Albisetti M, Halton J, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Svirin P, Kuhn T, Zapletal O, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Brueckmann M, Luciani M.

Blood. 2019 Dec 5. pii: blood.2019000998. doi: 10.1182/blood.2019000998. [Epub ahead of print]

3.

Multiplexed quantitative phosphoproteomics of cell line and tissue samples.

Kreuzer J, Edwards A, Haas W.

Methods Enzymol. 2019;626:41-65. doi: 10.1016/bs.mie.2019.07.027. Epub 2019 Aug 12.

PMID:
31606085
4.

Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study.

Levy JH, van Ryn J, Sellke FW, Reilly PA, Elsaesser A, Glund S, Kreuzer J, Weitz JI, Pollack CV Jr.

Ann Surg. 2019 Oct 9. doi: 10.1097/SLA.0000000000003638. [Epub ahead of print]

PMID:
31599808
5.

Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer.

Ligorio M, Sil S, Malagon-Lopez J, Nieman LT, Misale S, Di Pilato M, Ebright RY, Karabacak MN, Kulkarni AS, Liu A, Vincent Jordan N, Franses JW, Philipp J, Kreuzer J, Desai N, Arora KS, Rajurkar M, Horwitz E, Neyaz A, Tai E, Magnus NKC, Vo KD, Yashaswini CN, Marangoni F, Boukhali M, Fatherree JP, Damon LJ, Xega K, Desai R, Choz M, Bersani F, Langenbucher A, Thapar V, Morris R, Wellner UF, Schilling O, Lawrence MS, Liss AS, Rivera MN, Deshpande V, Benes CH, Maheswaran S, Haber DA, Fernandez-Del-Castillo C, Ferrone CR, Haas W, Aryee MJ, Ting DT.

Cell. 2019 Jun 27;178(1):160-175.e27. doi: 10.1016/j.cell.2019.05.012. Epub 2019 May 30.

PMID:
31155233
6.

Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.

Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, Kreuzer J, Cronin L, Cotton D, Grauer C, Brueckmann M, Chernyatina M, Donnan G, Ferro JM, Grond M, Kallmünzer B, Krupinski J, Lee BC, Lemmens R, Masjuan J, Odinak M, Saver JL, Schellinger PD, Toni D, Toyoda K; RE-SPECT ESUS Steering Committee and Investigators.

N Engl J Med. 2019 May 16;380(20):1906-1917. doi: 10.1056/NEJMoa1813959.

PMID:
31091372
7.

Mitochondrial Permeability Uncouples Elevated Autophagy and Lifespan Extension.

Zhou B, Kreuzer J, Kumsta C, Wu L, Kamer KJ, Cedillo L, Zhang Y, Li S, Kacergis MC, Webster CM, Fejes-Toth G, Naray-Fejes-Toth A, Das S, Hansen M, Haas W, Soukas AA.

Cell. 2019 Apr 4;177(2):299-314.e16. doi: 10.1016/j.cell.2019.02.013. Epub 2019 Mar 28.

PMID:
30929899
8.

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.

Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP.

Am Heart J. 2019 Jun;212:13-22. doi: 10.1016/j.ahj.2019.02.006. Epub 2019 Mar 1.

PMID:
30928824
9.

Auto-fatty acylation of transcription factor RFX3 regulates ciliogenesis.

Chen B, Niu J, Kreuzer J, Zheng B, Jarugumilli GK, Haas W, Wu X.

Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8403-E8412. doi: 10.1073/pnas.1800949115. Epub 2018 Aug 20.

10.

Identification of galectin-3 as an autoantigen in patients with IgG4-related disease.

Perugino CA, AlSalem SB, Mattoo H, Della-Torre E, Mahajan V, Ganesh G, Allard-Chamard H, Wallace Z, Montesi SB, Kreuzer J, Haas W, Stone JH, Pillai S.

J Allergy Clin Immunol. 2019 Feb;143(2):736-745.e6. doi: 10.1016/j.jaci.2018.05.011. Epub 2018 May 29.

11.

Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.

Goldhaber SZ, Schulman S, Eriksson H, Feuring M, Fraessdorf M, Kreuzer J, Schüler E, Schellong S, Kakkar A.

Thromb Haemost. 2017 Nov;117(11):2045-2052. doi: 10.1160/TH17-03-0176. Epub 2017 Oct 4.

PMID:
29202209
12.
13.

Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI.

N Engl J Med. 2017 Aug 3;377(5):431-441. doi: 10.1056/NEJMoa1707278. Epub 2017 Jul 11.

14.

Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER®, RE-COVER™ II, and RE-MEDY™.

Feuring M, Schulman S, Eriksson H, Kakkar AJ, Schellong S, Hantel S, Schueler E, Kreuzer J, Goldhaber SZ.

J Thromb Thrombolysis. 2017 May;43(4):484-489. doi: 10.1007/s11239-017-1479-z.

15.

Coupling of Homologous Recombination and the Checkpoint by ATR.

Buisson R, Niraj J, Rodrigue A, Ho CK, Kreuzer J, Foo TK, Hardy EJ, Dellaire G, Haas W, Xia B, Masson JY, Zou L.

Mol Cell. 2017 Jan 19;65(2):336-346. doi: 10.1016/j.molcel.2016.12.007. Epub 2017 Jan 12.

16.

Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™.

Goldhaber SZ, Eriksson H, Kakkar A, Schellong S, Feuring M, Fraessdorf M, Kreuzer J, Schueler E, Schulman S.

Vasc Med. 2016 Dec;21(6):506-514. Epub 2016 Nov 1.

PMID:
27807306
17.

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.

Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators.

Clin Cardiol. 2016 Oct;39(10):555-564. doi: 10.1002/clc.22572. Epub 2016 Aug 26.

18.

Electronic health records to facilitate clinical research.

Cowie MR, Blomster JI, Curtis LH, Duclaux S, Ford I, Fritz F, Goldman S, Janmohamed S, Kreuzer J, Leenay M, Michel A, Ong S, Pell JP, Southworth MR, Stough WG, Thoenes M, Zannad F, Zalewski A.

Clin Res Cardiol. 2017 Jan;106(1):1-9. doi: 10.1007/s00392-016-1025-6. Epub 2016 Aug 24. Review.

19.

Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II.

Goldhaber SZ, Schellong S, Kakkar A, Eriksson H, Feuring M, Kreuzer J, Fraessdorf M, Schulman S.

Thromb Haemost. 2016 Sep 27;116(4):714-21. doi: 10.1160/TH16-04-0271. Epub 2016 Jul 14.

PMID:
27411591
20.

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.

Glund S, Stangier J, van Ryn J, Schmohl M, Moschetti V, Haazen W, De Smet M, Gansser D, Norris S, Lang B, Reilly P, Kreuzer J.

Clin Pharmacokinet. 2017 Jan;56(1):41-54. doi: 10.1007/s40262-016-0417-0.

Supplemental Content

Loading ...
Support Center